Quinupristin-dalfopristin is active against Toxoplasma gondii.
Quinupristin-dalfopristin is active against Toxoplasma gondii.
复制标题
奎奴普汀-达福普汀对弓形虫有活性。
DOI：
10.1128/aac.43.8.2043
复制
发表时间：
1999
影响因子：
4.9
通讯作者：
Remington,JS
中科院分区：
文献类型：
--
作者：
Khan,AA;Slifer,TR;Araujo,FG;Remington,JS
测定了Synercid及其各组分（quinupristin和dalfoopristin）对刚地弓形虫的活性。在体外，协同酸及其两种成分均能抑制速殖子的胞内复制。synercid、quinupristin和dalfoopristin的50%抑制浓度分别为1.6、2.7和6.3 μg/ml。因此，协同酸明显比其组分更有活性。急性感染小鼠每天腹腔注射每公斤体重100或200毫克的协同酸10天，感染小鼠的存活率分别为50% （P= 0.0002）和100% (P< 0.0001)，而所有对照组小鼠在第18天死亡。相比之下，每天每公斤单独使用200毫克奎奴普汀和达福普汀治疗仅导致20%的生存率；每天每公斤服用任一药物50毫克只会延长死亡时间。这些结果表明，协同酸可能对治疗人类弓形虫病有用。
Synercid and each of its components (quinupristin and dalfopristin) were examined for their activities againstToxoplasma gondii. In vitro, intracellular replication of tachyzoites was inhibited by synercid and each of its two components. The 50% inhibitory concentrations of synercid, quinupristin, and dalfopristin were 1.6, 2.7, and 6.3 μg/ml, respectively. Thus, synercid was markedly more active than its components. Treatment of acutely infected mice with 100 or 200 mg of synercid per kg of body weight per day administered intraperitoneally for 10 days resulted in survival of 50% (P= 0.0002) and 100% (P< 0.0001) of infected mice, respectively, whereas all control mice died by day 18. In contrast, treatment with 200 mg of either quinupristin and dalfopristin per kg per day alone resulted in only 20% survival; treatment with 50 mg of either drug per kg per day resulted only in the prolongation of time to death. These results suggest that synercid may be useful for treatment of toxoplasmosis in humans.